MedTrace Logo

A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis

NCT07158151 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2026-04-29

No results posted yet for this study

Summary

This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis

Conditions

  • Atopic Dermatitis of Adults

Interventions

DRUG

RSS0393 ointment

RSS0393 ointment 0.05%

DRUG

RSS0393 ointment

RSS0393 ointment 0.01%

DRUG

RSS0393 ointment

RSS0393 ointment 0.03%

DRUG

RSS0393 ointment

RSS0393 ointment placebo

Sponsors & Collaborators

  • Reistone Biopharma Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-25
Primary Completion
2026-04-10
Completion
2026-04-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07158151 on ClinicalTrials.gov